Integrated Filing — IndAS



General information about company

Scrip Code 539523
NSE Symbol ALKEM
MSEI Symbol NOTLISTED
ISIN INE540L01014
Name of company ALKEM LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment The Company is exclusively engaged in pharmaceutical business
Start date and time of board meeting 13-11-2025   11:40:00
End date and time of board meeting 13-11-2025   13:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 29-05-2025
Indicate Company website link for updated RPT policy of the Company chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://admin.alkemlabs.com/uploads/Related_Party_Transactions_Policy_0999ee9848.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No defaults on loans and debt securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,54,203.00 4,91,420.00
Other income 10,137.00 21,795.00
Total income 2,64,340.00 5,13,215.00
2 Expenses
(a) Cost of materials consumed 56,763.00 1,18,296.00
(b) Purchases of stock-in-trade 12,284.00 20,635.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (260.00) 533.00
(d) Employee benefit expense 46,085.00 93,059.00
(e) Finance costs 1,275.00 2,554.00
(f) Depreciation, depletion and amortisation expense 5,859.00 11,748.00
(f) Other Expenses
1 Other Expenses 62,263.00 1,19,781.00
Total other expenses 62,263.00 1,19,781.00
Total expenses 1,84,269.00 3,66,606.00
3 Total profit before exceptional items and tax 80,071.00 1,46,609.00
4 Exceptional items 0.00 1,429.00
5 Total profit before tax 80,071.00 1,48,038.00
6 Tax expense
7 Current tax 12,356.00 23,290.00
8 Deferred tax (4,651.00) (9,844.00)
9 Total tax expenses 7,705.00 13,446.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 72,366.00 1,34,592.00
12 Profit (loss) from discontinued operations before tax 9,695.00 14,905.00
13 Tax expense of discontinued operations 3,388.00 5,208.00
14 Net profit (loss) from discontinued operation after tax 6,307.00 9,697.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 78,673.00 1,44,289.00
17 Other comprehensive income net of taxes (216.00) (431.00)
18 Total Comprehensive Income for the period 78,457.00 1,43,858.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,391.00 2,391.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 60.53 112.57
Diluted earnings (loss) per share from continuing operations 60.53 112.57
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 5.27 8.11
Diluted earnings (loss) per share from discontinued operations 5.27 8.11
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 65.8 120.68
Diluted earnings (loss) per share from continuing and discontinued operations 65.8 120.68
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 12 November 2025 and subsequently approved by the Board of Directors at its meeting held on 13 November 2025. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2025. 3. The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. Consequently the proposed transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. The figures for the previous period have been restated to give effect to the presentation requirement of Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its business to Alkem Wellness Limited. Key financial information of Discontinued Operations: Quarter ended 30.09.2025 Total Income : 5,622.8 Total expenses : 4,653.3 Profit before tax : 969.5 Total tax expense : 338.8 Net profit for the period : 630.7 Quarter ended 30.06.2025 Total Income : 3,558.2 Total expenses : 3,037.2 Profit before tax : 521.0 Total tax expense : 182.0 Net profit for the period : 339.0 Quarter ended 30.09.2024 Total Income : 5,172.5 Total expenses : 4,315.8 Profit before tax : 856.7 Total tax expense : 299.4 Net profit for the period : 557.3 Six months ended 30.09.2025 Total Income : 9,181.0 Total expenses : 7,690.5 Profit before tax : 1,490.5 Total tax expense : 520.8 Net profit for the period : 969.7 Six months ended 30.09.2024 Total Income : 8,903.9 Total expenses : 7,470.7 Profit before tax : 1,433.2 Total tax expense : 500.8 Net profit for the period : 932.4 Year ended 31.03.2025 Total Income : 18,974.9 Total expenses : 16,036.4 Profit before tax : 2,938.5 Total tax expense : 1,026.8 Net profit for the period : 1,911.7 4. The Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility. The said facility had been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to Rs 142.9 million had been classified and disclosed as an exceptional item in the results for the quarter ended 30 June 2025 and half year ended 30 September 2025. 5. The Company operates in one reportable business segment i.e. Pharmaceuticals, accordingly no separate disclosure of segment information has been made.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,44,984.00
Capital work-in-progress 7,301.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 11,597.00
Intangible assets under development 3,486.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 4,72,725.00
Trade receivables, non-current 0.00
Loans, non-current 969.00
Other non-current financial assets 91,810.00
Total non-current financial assets 5,65,504.00
Deferred tax assets (net) 1,52,991.00
Other non-current assets 14,922.00
Total non-current assets 9,00,785.00
2 Current assets
Inventories 1,47,595.00
Current financial asset
Current investments 65,226.00
Trade receivables, current 1,77,513.00
Cash and cash equivalents 4,850.00
Bank balance other than cash and cash equivalents 1,16,060.00
Loans, current 100.00
Other current financial assets 1,80,985.00
Total current financial assets 5,44,734.00
Current tax assets (net) 0.00
Other current assets 62,574.00
Total current assets 7,54,903.00
3 Non-current assets classified as held for sale 89,845.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 17,45,533.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,391.00
Other equity 13,64,087.00
Total equity attributable to owners of parent 13,66,478.00
Non controlling interest
Total equity 13,66,478.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 16,879.00
Total non-current financial liabilities 16,879.00
Provisions, non-current 27,151.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 1,900.00
Total non-current liabilities 45,930.00
Current liabilities
Current financial liabilities
Borrowings, current 79,696.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 3,487.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,33,907.00
Total Trade payable 1,37,394.00
Other current financial liabilities 38,341.00
Total current financial liabilities 2,55,431.00
Other current liabilities 12,992.00
Provisions, current 14,828.00
Current tax liabilities (Net) 13,280.00
Deferred government grants, Current 0.00
Total current liabilities 2,96,531.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 36,594.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,79,055.00
Total equity and liabilites 17,45,533.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 In respect of continuing operations: -31300000 -62700000
2 In respect of discontinued operations: -1900000 -3600000
Total Amount of items that will not be reclassified to profit and loss (332.00) (663.00)
2 Income tax relating to items that will not be reclassified to profit or loss (116.00) (232.00)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (216.00) (431.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,48,038.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,687.00
Adjustments for decrease (increase) in inventories 601.00
Adjustments for decrease (increase) in trade receivables, current (18,600.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (12,265.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (2,164.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 12,172.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 408.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (273.00)
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 2,947.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 13,148.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,339.00)
Net cash flows from (used in) operations 1,46,699.00
Dividends received (408.00)
Interest paid 0.00
Interest received (16,297.00)
Income taxes paid (refund) 19,067.00
Other inflows (outflows) of cash (158.00)
Net cash flows from (used in) operating activities 1,10,769.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 10,804.00
Purchase of property, plant and equipment 13,810.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 1,91,510.00
Purchase of other long-term assets 3,44,700.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 408.00
Interest received 13,415.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 158.00
Net cash flows from (used in) investing activities (1,42,215.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 44,166.00
Repayments of borrowings 0.00
Payments of lease liabilities 1,490.00
Dividends paid 9,565.00
Interest paid 1,550.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 31,561.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 115.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 115.00
Cash and cash equivalents cash flow statement at beginning of period 1,204.00
Cash and cash equivalents cash flow statement at end of period 1,319.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 S&B Pharma LLC The Pharma Network LLC Fellow Subsidiary Company Sale of goods or services Not Applicable 5,654.50 3,562.60 372.60
2 The Pharma Network LLC S&B Pharma LLC Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 77.80 0.00 0.00
3 Pharmacor Pty Limited Alkem Laboratories Corporation Fellow Subsidiary Company Any other transaction Reimbursement of expenses to counterparty Not Applicable 37.70 14.40 16.20
4 Alkem Laboratories Limited Mr Aniruddha Singh Relative of Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 24.20 0.00 0.00
5 Alkem Laboratories Limited Mr Basudeo Narain Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 1,106.50 0.00 0.00
6 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Purchase of goods or services 40,000.00 Approved by the audit committee of the entity 6,073.20 1,708.50 2,893.80
7 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Services received 1,000.00 Approved by the audit committee of the entity 292.50 1,708.50 2,893.80
8 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Royalty expenses 1,000.00 Approved by the audit committee of the entity 1.20 1,708.50 2,893.80
9 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Rent Income 500.00 Approved by the audit committee of the entity 21.30 0.00 0.00
10 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Sale of goods or services 1,000.00 Approved by the audit committee of the entity 116.40 315.70 452.00
11 Alkem Laboratories Limited Alkem Laboratories Korea Inc. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 0.60 0.00 0.00
12 Alkem Laboratories Limited Ascend GmbH Subsidiary Sale of goods or services 25,000.00 Approved by the audit committee of the entity 13,152.30 8,267.30 10,821.60
13 Alkem Laboratories Limited Ascend GmbH Subsidiary Any other transaction Guarantee commission 200.00 Approved by the audit committee of the entity 1.90 0.00 0.00
14 Alkem Laboratories Limited Ascend GmbH Subsidiary Any other transaction Reimbursement of expenses to counterparty 2,400.00 Approved by the audit committee of the entity 926.80 592.40 1,605.60
15 Alkem Laboratories Limited Ascend Laboratories (Pty) Ltd Subsidiary Sale of goods or services 2,000.00 Approved by the audit committee of the entity 418.40 977.00 363.60
16 Alkem Laboratories Limited Ascend Laboratories (Pty) Ltd Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.20 0.00 0.00
17 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Sale of goods or services 11,400.00 Approved by the audit committee of the entity 4,610.60 5,042.20 5,682.00
18 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 1.20 0.00 0.00
19 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 800.00 Approved by the audit committee of the entity 373.70 579.40 1,001.80
20 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Subsidiary Any other transaction Reimbursement of expenses to counterparty 500.00 Approved by the audit committee of the entity 22.10 118.10 145.20
21 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Sale of goods or services 3,500.00 Approved by the audit committee of the entity 1,209.90 1,701.80 1,912.40
22 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Services rendered 1,500.00 Approved by the audit committee of the entity 117.90 0.00 1,912.40
23 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.10 0.00 0.00
24 Alkem Laboratories Limited Ascend Laboratories SDN BHD. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 0.40 0.00 0.00
25 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 24.50 0.00 0.00
26 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Sale of goods or services 40,000.00 Approved by the audit committee of the entity 9,622.90 7,487.70 6,589.30
27 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 26.80 0.00 0.00
28 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Services rendered 500.00 Approved by the audit committee of the entity 43.80 7,487.70 6,589.30
29 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Subsidiary Sale of goods or services 5,000.00 Approved by the audit committee of the entity 744.90 187.20 950.60
30 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by us 500.00 Approved by the audit committee of the entity 42.70 7,487.70 6,589.30
31 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by party 300.00 Approved by the audit committee of the entity 75.80 169.30 219.40
32 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Sale of goods or services 2,28,600.00 Approved by the audit committee of the entity 76,728.80 74,794.10 67,029.90
33 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Royalty income 1,100.00 Approved by the audit committee of the entity 183.20 74,794.10 67,029.90
34 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Services rendered 1,500.00 Approved by the audit committee of the entity 814.40 74,794.10 67,029.90
35 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Reimbursement of expenses to counterparty 10,000.00 Approved by the audit committee of the entity 735.30 9,315.50 6,540.10
36 Alkem Laboratories Limited Pharma Network SpA Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 5.00 0.00 0.00
37 Alkem Laboratories Limited Pharma Network SpA Subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 16.40 13.20 0.00
38 Alkem Laboratories Limited Pharmacor Limited Subsidiary Sale of goods or services 3,000.00 Approved by the audit committee of the entity 468.80 915.60 743.80
39 Alkem Laboratories Limited Pharmacor Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.30 0.00 0.00
40 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Sale of goods or services 28,400.00 Approved by the audit committee of the entity 10,993.40 10,893.10 12,339.70
41 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.10 0.00 0.00
42 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 3,800.00 Approved by the audit committee of the entity 554.40 2,191.60 1,532.50
43 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Services rendered 1,500.00 Approved by the audit committee of the entity 14.10 10,893.10 12,339.70
44 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 5.80 10,893.10 12,339.70
45 Alkem Laboratories Limited S&B Pharma LLC Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 81.20 704.20 431.00
46 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Sale of goods or services 16,000.00 Approved by the audit committee of the entity 34.20 6,980.40 4,494.70
47 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 137.20 0.00 137.20
48 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 1.50 0.00 0.00
49 Alkem Laboratories Limited Dr Meghna Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 30.00 Approved by the audit committee of the entity 15.00 0.00 0.00
50 Alkem Laboratories Limited Dr Divya Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 100.00 Approved by the audit committee of the entity 15.00 0.00 0.00
51 Alkem Laboratories Limited Mr Rajeev Kher Key Management Personnel Any other transaction Commission As per approval of Board of Directors or Shareholders of the entity as necessary 15.50 0.00 0.00
52 Alkem Laboratories Limited Mrs Madhurima Singh Key Management Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 9.90 0.00 0.00
53 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 5.20 0.00 0.00
54 Alkem Laboratories Limited Dr Divya Singh Relatives of Key Managerial Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 5.70 0.00 0.00
55 Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Mr Harish Lad Subsidiary and its KMP Any other transaction Reimbursement of expenses by counterparty Not Applicable 0.30 0.00 0.00
56 Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Mr Umesh Chatrala Subsidiary and its KMP Any other transaction Professional fees Not Applicable 0.60 0.00 0.00
57 Alkem Medtech Private Limited Mr Arun Purwar Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 3.10 0.00 0.00
58 Alkem Medtech Private Limited Mr Kaustav Banerjee Subsidiary and its KMP Any other transaction Reimbursement of expenses by counterparty Not Applicable 1.70 0.00 0.00
59 Alkem Medtech Private Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Fellow Subsidiary Company Investment As per approval of Board of Directors or Shareholders of the entity as necessary 10,856.50 0.00 10,856.50 Investment 0.00 NA Unsecured Business Requirement
60 Adroit Biomed Ltd Mr Sameer Paigankar Subsidiary and its KMP Any other transaction Reimbursement of expenses by counterparty Not Applicable 2.60 0.00 0.00
61 Adroit Biomed Ltd Mr Sushant Raorane Subsidiary and its KMP Any other transaction Professional fees Not Applicable 36.10 0.00 0.00
62 Adroit Biomed Ltd Mr Sushant Raorane Subsidiary and its KMP Any other transaction Reimbursement of expenses by counterparty Not Applicable 3.00 0.00 0.00
63 Adroit Biomed Ltd Pharmaserve Health Care Pvt. Ltd. Subsidiary and its related party Purchase of goods or services Not Applicable 36.90 0.00 0.00
64 Adroit Biomed Ltd Nutragenix Healthcare Pvt. Ltd. Subsidiary and its related party Any other transaction Business Support service Not Applicable 4.20 0.00 0.00
65 Alkem Laboratories Limited Mr Manish Narang Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 114.70 0.00 0.00
66 Alkem Laboratories Limited Mr Mritunjay Kumar Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 589.80 0.00 0.00
67 Alkem Laboratories Limited Mr Nitin Agrawal Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 197.30 0.00 0.00
68 Alkem Laboratories Limited Mr A K Purwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 10.40 0.00 0.00 Textual Information(1)
69 Alkem Laboratories Limited Ms Sangeeta Singh Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 9.90 0.00 0.00 Textual Information(2)
70 Alkem Laboratories Limited Ms Sudha Ravi Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 10.40 0.00 0.00 Textual Information(3)
71 Alkem Laboratories Limited Mr Narendra Kumar Aneja Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 17.00 0.00 0.00
72 Alkem Laboratories Limited Mr Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 635.40 0.00 0.00
73 Alkem Laboratories Limited Mr Sarandhar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 352.00 0.00 0.00
74 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 234.30 0.00 0.00
75 Alkem Laboratories Limited Mr Satish Kumar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 360.30 0.00 0.00
76 Alkem Laboratories Limited Mr R L Shenoy Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 7.20 0.00 0.00 Textual Information(4)
77 Alkem Laboratories Limited Ms Neela Bhattacherjee Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 6.70 0.00 0.00 Textual Information(5)
78 Alkem Laboratories Limited Mr Diwakar Gupta Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 7.20 0.00 0.00 Textual Information(6)
79 Alkem Laboratories Limited Mr Sujjain Talwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 15.50 0.00 0.00
80 Alkem Laboratories Limited Mr Srinivas Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 547.90 0.00 0.00
81 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 1.70 0.00 0.00
82 Alkem Laboratories Limited Mr Sandeep Singh Key Management Personnel Any other transaction Commission As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 200.00 0.00 0.00
83 Alkem Laboratories Limited Mr Sandeep Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 278.20 0.00 0.00
84 Alkem Laboratories Limited Mr Sarandhar Singh Relatives of Key Managerial Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 18.40 0.00 0.00
85 Alkem Laboratories Limited Mr Srinivas Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 84.30 0.00 0.00
86 Alkem Laboratories Limited Mr Nitin Agrawal Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 1.00 0.00 0.00
87 Alkem Laboratories Limited Mr Manish Narang Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 0.10 0.00 0.00
88 Ascend Laboratories, SpA Pharma Network SpA Fellow Subsidiary Company Sale of goods or services Not Applicable 5,360.30 2,047.20 3,104.40
89 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Purchase of goods or services 15,000.00 Approved by the audit committee of the entity 3,046.70 1,301.20 1,874.60
90 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Sale of goods or services 1,000.00 Approved by the audit committee of the entity 14.00 1,301.20 1,874.60
91 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Services received 9,000.00 Approved by the audit committee of the entity 1,805.50 1,301.20 1,874.60
92 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Rent Income 300.00 Approved by the audit committee of the entity 81.90 1,301.20 1,874.60
93 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Purchase of goods or services 40,000.00 Approved by the audit committee of the entity 9,499.60 2,408.00 2,764.40
94 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Royalty income 2,000.00 Approved by the audit committee of the entity 283.30 595.00 1,676.80
95 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Guarantee commission 700.00 Approved by the audit committee of the entity 74.90 0.00 0.00
96 Alkem Laboratories Limited Galpha Laboratories Limited Affiliate Purchase of goods or services 800.00 Approved by the audit committee of the entity 276.10 159.10 49.50
97 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Services received 2,000.00 Approved by the audit committee of the entity 441.00 253.10 278.40
98 Alkem Laboratories Limited Alkem Foundation Subsidiary Any other transaction Donations given 4,500.00 Approved by the audit committee of the entity 422.90 0.00 0.00
99 Indchemie Health Specialities Private Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Sale of goods or services Approved by the audit committee of the entity 187.90 34.20 7.30
100 Alkem Laboratories Limited Dr Vikas Gupta Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 1,085.30 0.00 0.00
101 Alkem Laboratories Limited Mrs Madhurima Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 633.70 0.00 0.00
102 Indchemie Health Specialities Private Limited Mr Mritunjay Kumar Singh Subsidiary and KMP Any other transaction Rent expenses Not Applicable 1.20 0.00 0.00
103 Cachet Pharmaceuticals Private Limited Galpha Laboratories Limited Affiliate Purchase of goods or services Approved by the audit committee of the entity 59.30 38.20 2.90
104 Enzene Biosciences Limited Enzene Inc Fellow Subsidiary Company Investment Approved by the audit committee of the entity 2,602.50 20,660.00 23,262.50 Investment 0.00 NA Unsecured Business Requirements
105 Enzene Biosciences Limited Enzene Inc Fellow Subsidiary Company Loan Approved by the audit committee of the entity 18,160.00 19,040.00 39,360.00 Loan 9.05 7 Unsecured Business Requirements
106 Cachet Pharmaceuticals Private Limited Mr. Arunkumar Deshmukh Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.80 0.00 0.00
107 The Pharma Network LLC Mr. Sandeep Singh Subsidiary and its KMP Remuneration As per approval of Board of Directors. 409.50 0.00 0.00
108 Cachet Pharmaceuticals Private Limited Mr VIRENDRA V. YAGNIK Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.10 0.00 0.00
109 Cachet Pharmaceuticals Private Limited Dr Anuja Sinha Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.60 0.00 0.00
110 Indchemie Health Specialities Private Limited Mr Akhouri Maheshwari Prasad Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 7.00 0.00 0.00
111 Indchemie Health Specialities Private Limited Mr Gautam Gulabchand Parekh Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 7.20 0.00 0.00
112 Enzene Biosciences Limited Ms. Sangeeta Singh Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 2.40 0.00 0.00
113 Enzene Biosciences Limited Ms. Sudha Ravi Subsidiary and its KMP Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 2.40 0.00 0.00
114 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Guarantee commission 200.00 Not Applicable 19.20 0.00 0.00
115 Ascend GmbH Enzene Biosciences Limited Fellow Subsidiary Company Any other transaction Reimbursement of expenses to counterparty Not Applicable 154.40 201.00 395.80
116 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Sale of goods or services 2,000.00 Approved by the audit committee of the entity 0.80 0.00 0.00
117 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 2,000.00 Approved by the audit committee of the entity 0.10 2.30 5.60
118 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 10.20 2.30 5.60
119 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 2,500.00 20.00 2,520.00 Investment 0.00 NA Unsecured Business Requirements
120 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 100.00 Approved by the audit committee of the entity 0.00 97.50 97.60
121 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 65,000.00 500.00 65,500.00 Investment 0.00 NA Unsecured Business Requirements
122 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 2,500.00 Approved by the audit committee of the entity 1.30 302.80 304.00
123 Ascend Laboratories, SpA Pharmacor SPA Fellow Subsidiary Company Sale of goods or services Not Applicable 2,742.00 0.00 2,363.00
124 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Reimbursement of expenses by counterparty 100.00 Approved by the audit committee of the entity 10.30 0.00 0.00
125 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Dividend Received from subsidiary As per approval of Board of Directors or Shareholders of the entity as necessary 408.00 0.00 0.00
126 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 0.70 0.00 0.00
127 Alkem Laboratories Limited Pharmacor SPA Subsidiary Any other transaction Guarantee commission 100.00 Not Applicable 3.10 0.00 0.00
128 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Rent Income 50.00 Approved by the audit committee of the entity 0.60 2.30 5.60
129 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Rent Income 500.00 Approved by the audit committee of the entity 17.20 302.80 304.00
130 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Security Deposit received Not Applicable 50.10 0.00 50.10
Total value of transaction during the reporting period 2,65,692.00



Text Block

Textual Information(1) upto 12 July 2025
Textual Information(2) upto 12 July 2025
Textual Information(3) upto 12 July 2025
Textual Information(4) with effect from 13 July 2025
Textual Information(5) with effect from 13 July 2025
Textual Information(6) with effect from 13 July 2025